25 Oct 2016 16:59
25 October 2016
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
The following amendment has been made to the 'Director Dealing' announcement released on 25 October 2016 at 15.01 under RNS No. 4259N. Lord David Evans no longer holds any shares.
Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that between 19 August 2016 and 16 September 2016 Lord David Evans, a Non-Executive Director of the Company, disposed of 136,296 ordinary shares of 25 pence each in the Company ("Ordinary Shares"), at a weighted average price of 121 pence per share.
Following these transactions, Lord Evans no longer holds any Ordinary Shares of the Company.
Advanced Oncotherapy Plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman & CEO | Tel: +44 20 3617 8728 |
Nicolas Serandour, CFO & COO | |
Stockdale Securities (Nomad & Joint Broker) | |
Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
Beaufort Securities (Joint Broker) | |
Jon Belliss / Elliot Hance | Tel: +44 20 7382 8300 |
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Advanced Oncotherapy (AVO)